U.S. regulators told Novartis to discontinue a print ad that allegedly overstated the benefits of irritable bowel drug Zelnorm and omitted important safety information. The ad did not mention the drug ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback